In summary, our findings suggest that the combination of chemotherapy, anti-LIF, and anti-PD-L1 synergistically enhances antitumor activity in PDAC through both tumor-intrinsic and immune-mediated mechanisms. This evidence concerns the gene LIF and neoplasm.